Armata Pharmaceuticals received two new US patents for its bacteriophage programs, AP-SA02 and AP-PA02, extending protection until at least 2041.
Why it matters. Armata's strengthened IP portfolio enhances its competitive position in the field of bacteriophage therapeutics, protecting its lead candidates and potentially delaying competition.
using its proprietary bacteriophage-based technology
the company's global IP portfolio consists of 101 issued patents (15 U.S. and 86 ex-U.S.) and 60 pending patent applications (9 U.S. and 51 ex-U.S.) with nominal expiration dates through 2046.
Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041
These newly issued U.S. patents support Armata's leadership in bacteriophage therapeutics and specifically, strengthen the intellectual property ("IP") around the AP-SA02 and AP-PA02 programs, which are highly impactful and potential first- and best-in-class therapies. With pate…
Issued on October 6, 2026, protects methods of treating Staphylococcus aureus infections using its lead product candidate, AP-SA02, which is currently in development for adjunct treatment of complicated Staphylococcus aureus bacteremia ("SAB") caused by methicillin-sensitive S.…
